Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Unilateral U/S PVB 1Stomach Neoplasms 1Pain, Postoperative 1Lung Neoplasms 1Liver Neoplasms 1Liver Diseases 1Head and Neck Neoplasms 1Epstein-Barr Virus Infections 1Diarrhea 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Pemetrexed 10Cisplatin 9Erlotinib Hydrochloride 8Carboplatin 7icotinib 5Gefitinib 5Docetaxel 5endostar protein 3Zoledronic Acid 3Radiotherapy 3Paclitaxel 3Gemcitabine 3Endostatins 3Afatinib 3tislelizumab 2pembrolizumab 2osimertinib 2lorlatinib 2flurbiprofen axetil 2dexamethasone 21-phosphate 2atezolizumab 2Vinorelbine 2Surgical Procedures, Operative 2Saline Solution 2Nivolumab 2Drug Therapy 2Dexamethasone 2Chemoradiotherapy 2trametinib 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Carcinoma, Non-Small-Cell Lung × Control Groups × Clear all
NCT00813332 2010-01-25

Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)

Simcere Pharmaceutical Co., Ltd

Phase 4 Unknown
300 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡